Telix 2026 Half-Year Results: Strong Commercial Execution and Momentum in Late-Stage Pipeline

Telix Pharmaceuticals Limited (TLX) Q2 2026 Earnings Call Transcript

Telix Pharmaceuticals Limited (TLX) Q2 2026 Earnings Call August 19, 2026 7:00 PM EDTCompany ParticipantsKyahn Williamson - Senior Vice President of...

Telix 2026 Half-Year Results: Strong Commercial Execution and Momentum in Late-Stage Pipeline

MELBOURNE, Australia and INDIANAPOLIS, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces its financial results for the period ended June 30, 2026.

Telix Pharmaceuticals delivers robust half-year earnings and pipeline progress

The radiopharmaceuticals company has handed down its half-year results this morning. The post Telix Pharmaceuticals delivers robust half-year earnings and pipeline progress appeared first on The Motley Fool Australia.

HotCopper Highlights: Zip dominates investor attention as Telix, Liontown and American Tungsten trend

Welcome to HotCopper Highlights for Week 34, where we take a look at the stocks that got investors talking and attracted the most attention. It’s been another big week for retail investors, with earnings season putting the spotlight on some of popular ASX growth names. One of the most watched stocks of the week was Telix Pharmaceuticals (ASX: TLX). It’s been in the spotlight following its half-year results. Telix reported a 22 per cent increase …

Telix half-year revenue increases 22 per cent to 477 million dollars

MELBOURNE, Australia and INDIANAPOLIS, Aug. 20, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces its financial results for the period ended June 30, 2026. H1 2026 key results Group performance[1]: Double-digit revenue growth and gross margin improvement Group revenue of US$477 million, up 22%[2] year-over-year, tracking in line with the upper end of full year guidance of US$950 million to US$97…